复方苦参注射液联合多西他赛治疗一线化疗失败非小细胞肺癌患者的疗效

[目的]探讨复方苦参注射液联合多西他赛对一线化疗失败非小细胞肺癌(NSCLC)患者的疗效及血清肿瘤标记物的影响.[方法]80例一线化疗失败的NSCLC患者随机分为观察组(复方苦参注射液+多西他赛)与对照组(多西他赛),比较两组近期疗效、不良反应、治疗前后血清肿瘤标记物水平及细胞免疫功能变化,并随访统计两组总生存期(OS)、无进展生存期(PFS).[结果]观察组近期有效率和疾病控制率分别为25.00%(10/25)和62.50%(25/40),明显高于对照组的10.00%(4/40)和37.50%(15、40),且差异有显著性(P<0.05);两组各不良反应发生率比较差异无显著性(P>0.05);与治疗前比较,两组治疗后血清癌胚抗原(CEA)、糖类抗原-125(CA-125)、细胞角蛋白19片段(CYFRA21-1)水平均显著下降(P<0.05),且观察组治疗后上述指标均显著低于对照组(P<0.05);观察组中位OS、PFS分别为13.50个月、9.00个月,明显长于对照组的10.20个月、7.40个月,且差异有显著性(P<0.05).[结论]复方苦参注射液联合多西他赛能明显降低NSCLC患者血清肿瘤标记物,改善机体细胞免疫功能,延长OS、PFS,且不增加毒副反应.

Effect of Compound Kushen Injection Combined with Docetaxel on NSCLC Patient after the Failure of First-line Chemotherapy Treatment

[Objective]To investigate the effect of compound Kushen injection combined with Docetaxel on ser-um tumor markers in patients with non-small cell lung cancer(NSCLC)after the failure of first-line chemotherapy treatment.[Methods]A total of 80 patients with NSCLC after the failure of first-line chemotherapy treatment were randomly divided into observation group(treated with compound Kushen injection combined with docetaxel) and control group(treated with docetaxel).The short-term efficacy,adverse reactions,serum tumor markers lev-els before and after treatment and changes of cellular immune function were compared between the two groups,OS and PFS of the two groups were statistically analyzed.[Results] The short-term effective rate and disease control rate of the observation group were 25%(10/25)and 62.50%(25/40),respectively,which were significantly higher than 10%(4/40)and 37.50%(15,40)of the control group,and the difference was significant(P <0.05);There was no significant difference in the incidence of adverse reactions between the two groups(P >0.05);Compared with before treatment,the levels of serum carcinoembryonic antigen(CEA),carbohydrate anti-gen-125(CA-125)and cytokeratin 19 fragment(CYFRA21-1)were significantly decreased in the two groups af-ter treatment(P <0.05),and the above indexes in the observation group were significantly lower than those in the control group(P <0.05);The median OS and PFS in the observation group were 13.50 months and 9 months respectively,which were significantly longer than those in the control group at 10.20 months and 7.40 months, and the difference was significant(P <0.05).[Conclusion]Compound Kushen injection combined with docetaxel can significantly reduce the serum tumor markers in patients with NSCLC,improve the cellular immune function, prolong OS,PFS,and do not increase toxicity.